SAN FRANCISCO, Feb. 12, 2008 (Thomson Financial delivered by Newstex) -- Genentech (NYSE:DNA) Inc. late Tuesday said that Avado, a Phase III study evaluating its cancer drug Avastin in combination with docetaxel chemotherapy, met its primary endpoint of prolonging progression-free survival in patients with advanced breast cancer. The Roche-sponsored Avado study investigated the addition of Avastin administered in two different dosages in combination with chemotherapy. Both doses of Avastin in combination with chemotherapy showed ‘statistically significant improvement’ in the time patients lived without their disease advancing compared with chemotherapy and placebo, based on investigator assessments, the South San Francisco, Calif.-based biotechnology company said.
